Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity

Summary

This study investigates the efficacy and safety of once weekly injectable MET097 in adult participants with obesity or overweight with weight-related comorbidities excluding T2D. This trial will last for a duration of 84 weeks. The primary endpoint will be assessed after 64 weeks of treatment with the secondary at 84 weeks.

Timeline

Start

2025-12-19

Primary completion

2027-09-21

Completion

2028-04-25

Drugs

Indications